Predicine announces launch of PredicineALERT and 12 clinical studies at AACR conference

Predicine presented data from 12 studies and introduced PredicineALERT™, a next-generation Minimal Residual Disease (MRD) liquid biopsy assay at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Florida, USA. PredicineALERT provides a generalized approach to MRD testing, an assay without the requirement for personalized individual probe designs, but instead utilizes methylation profiling.

Key highlights of the PredicineALERT MRD assay include:

• Tumor-naive MRD detection without the need of personalization
• Fast turn-around-time (TAT) down to 6 days
• Sample input using as low as 2.5 ng cell-free DNA

Predicine also presented twelve posters demonstrating the clinical utility and effectiveness of Predicine’s liquid biopsy platform across a multitude of indications, clinical trials, and profiling applications.

“Predicine is excited to introduce the next-generation MRD assay, PredicineALERT,” said Shidong Jia, Founder and global CEO of Predicine. “The PredicineALERT assay represents a methylation-based approach to MRD testing without personalization, minimizing the operational burden from the current tumor-informed personalized MRD assay. In collaboration with our biopharma and academic partners, we are glad to see the analytical and clinical feasibility data utilizing cell-free DNA (cfDNA) to enable global clinical trials, CDx development, and patient testing.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>